Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 32 studies. IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure and Immunotherapy Study Status Enrolling IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Closed to Accrual IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded P1113: AERAS-404 TB Vaccine in BCG-Primed Infants DAIDS Number 11911 Research Area Tuberculosis Study Status Closed to Follow Up P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls DAIDS Number 11878 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics Pagination Current page 1 Page 2 Page 3 Page 4 Next page Next
IMPAACT 2042: Tatelo Plus DAIDS Number 39076 Research Area Cure and Immunotherapy Study Status Enrolling
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling
IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development
IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded
P1113: AERAS-404 TB Vaccine in BCG-Primed Infants DAIDS Number 11911 Research Area Tuberculosis Study Status Closed to Follow Up
P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls DAIDS Number 11878 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics
